Therefore, we aimed to establish a highly sensitive time‐resolved fluorescence immunoassay (TRFIA)14 and evaluate its application for detecting IL‐18 in the serum of liver cancer, hepatitis B, hepatitis C, autoimmune hepatitis, and fatty liver disease patients. Here, IL18 is linked to liver cancer.